Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.

@article{Laak2010RecognitionOI,
  title={Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.},
  author={Maureen A ter Laak and Alphons H Temmink and Ankie Koeken and Nils E van 't Veer and Paul R M van Hattum and Christa Maria Cobbaert},
  journal={Pediatric neurology},
  year={2010},
  volume={43 3},
  pages={159-62}
}
Ten out of 100 children treated for attention deficit hyperactivity disorder with standard doses of atomoxetine were selected by a neurologist for cytochrome P450 2D6 and cytochrome P450 2C19 genotyping, based on late response (>9 weeks) and adverse effects (gastrointestinal problems, sleeping disorders, malaise, inactivity, and mood instabilities). After genotyping, eight children were confirmed to have compromised cytochrome P450 2D6 activity because of at least one nonfunctional or less… CONTINUE READING